Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

Impact · against what's priced in

Verastem (VSTM) provides a concrete catalyst path with a projected Q2 2027 filing for VS-7375 in pancreatic cancer and early 2027 data readouts for combinations. The reported 41% response rate in pancreatic cancer and 44% in colorectal cancer (exceeding the 30% benchmark) provide strong clinical validation for the KRAS G12D program.

VSTM+0.70: No priced-in read yet

Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

What matters in this story

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

What matters in this story

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

How each ticker is affected

Track these names every morning.

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

Coherus Oncology: 3 Key Takeaways for Long-Term Investors

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

What matters in this story

Next reads from the same story arc

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans

What matters in this story

Next reads from the same story arc

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

How each ticker is affected

Track these names every morning.

FDA Rejects NovoCure's Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.

Coherus Oncology: 3 Key Takeaways for Long-Term Investors

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline